In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CRO Patheon nets $570.5mm in IPO

Executive Summary

Patheon NV (formerly Patheon Holdings Cooperatief UA) netted $570.5mm in its IPO through the sale of 29.5mm shares (including full exercise of the 4.5mm overallotment option shares) at $21 (midpoint of range). The selling stockholder also sold 4.8mm shares in the offering. The company's principal shareholders are private equity firm JLL Partners and Dutch science company Koninklijke DSM NV.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies